Joining VeloClub not only supports the work we do, there are some fantastic benefits:
by Mark Zalewski
January 24, 2017
In today’s CyclingTips Daily News Digest: The Status of Women’s Cycling – Part 1: A Discussion with Iris Slappendel; British Cycling CEO steps-down earlier than expected; Nicole Cooke to give testimony to British Parliament committee; Promising British cyclocross racer passes away; Former U23 World Champion dies of heart attack; Thalita De Jong out of World Championships; Equal prize money for 2017 HSBC UK National Women’s Road Series; Boonen to ride disc brakes during final season; Sport doping documentary that began with cycling premieres at Sundance; Multiple lawsuits filed over new Lemond carbon fibre company; Wiggins says reality TV decision based on maintaining fitness; Telenet UCI World Cup Hoogerheide highlights; Backstage Pass – Tour Down Under final stages.
Former world and Olympic champion Nicole Cooke is set to appear before the British Parliament’s Culture, Media and Sport Select Committee, chaired by MP Damian Collins, to give testimony regarding doping in sport. This is the same committee that Dave Brailsford, Shane Sutton and British Cycling president Bob Howden testified before in December.
Nicole Cooke wins the 2003 Women’s Amstel Gold Race ahead of Australia’s Olivia Gollan.
Cooke recently wrote an op-ed in The Guardian in which she said British Cycling has many questions to answer, both in terms of doping and what she referred to as widespread sexism within the organisation, following an earlier article she wrote during the Shane Sutton sexism allegations.
Cooke retired from professional racing in 2013 and has always been outspoken in her contempt for doping cheats, and her testimony on Tuesday is expected to be as harsh as ever.
Earlier in 2016 she weighed-in on the missed tests of Lizzie Armitstead, saying she had advised UK Anti-Doping of problems within the system.
“When I brought this up with UKAD as too permissive a regime, allowing the drug cheats too much latitude, I was advised that regular late changes to availability would be noted and would then draw more targeted testing on that individual. I hope that is the case.”